John W Smither Arcutis Biotherapeutics, Inc. (ARQT) insider trading activity

John W Smither is Chief Financial Officer of Arcutis Biotherapeutics, Inc.. Currently has a direct ownership of 11,365 shares of ARQT, which is worth approximately $169,679. The most recent transaction as insider was on Feb 13, 2024, when has been sold 11,365 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 11.4K

0% 3M change

75.46% 12M change

Total Value Held $169,679

John W Smither Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 13 2024	BUY Grant, award, or other acquisition	-	11,365 Added 50.0%	11,365 Common Stock
Mar 10 2021	SELL Open market or private sale	$16,450 $32.9 p/Share	500 Reduced 1.07%	46,321 Common Stock
Mar 10 2021	BUY Exercise of conversion of derivative security	$840 $1.68 p/Share	500 Added 1.06%	46,821 Common Stock
Mar 04 2021	BUY Exercise of conversion of derivative security	$20,825 $1.68 p/Share	12,396 Added 21.11%	46,321 Common Stock
Mar 03 2021	BUY Grant, award, or other acquisition	-	9,500 Added 21.88%	33,925 Common Stock
Mar 01 2021	SELL Open market or private sale	$26,437 $34.2 p/Share	773 Reduced 3.07%	24,425 Common Stock
Feb 10 2021	SELL Open market or private sale	$26,730 $35.64 p/Share	750 Reduced 2.89%	25,198 Common Stock
Feb 10 2021	BUY Exercise of conversion of derivative security	$1,260 $1.68 p/Share	750 Added 2.81%	25,948 Common Stock
Feb 01 2021	SELL Open market or private sale	$43,750 $35.0 p/Share	1,250 Reduced 4.73%	25,198 Common Stock
Feb 01 2021	BUY Exercise of conversion of derivative security	$2,100 $1.68 p/Share	1,250 Added 4.51%	26,448 Common Stock
Jan 19 2021	SELL Open market or private sale	$15,000 $30.0 p/Share	500 Reduced 1.95%	25,198 Common Stock
Jan 19 2021	BUY Exercise of conversion of derivative security	$840 $1.68 p/Share	500 Added 1.91%	25,698 Common Stock
Dec 14 2020	SELL Open market or private sale	$45,000 $30.0 p/Share	1,500 Reduced 5.62%	25,198 Common Stock
Dec 14 2020	BUY Exercise of conversion of derivative security	$2,520 $1.68 p/Share	1,500 Added 5.32%	26,698 Common Stock
Sep 29 2020	SELL Open market or private sale	$15,000 $30.0 p/Share	500 Reduced 2.05%	23,875 Common Stock
Sep 29 2020	BUY Exercise of conversion of derivative security	$840 $1.68 p/Share	500 Added 2.01%	24,375 Common Stock

Also insider at

EFTR

eFFECTOR Therapeutics, Inc. Healthcare

Director

AMTI

Applied Molecular Transport Inc. Healthcare

Director

GNLX

GENELUX CORP

NAMS

NewAmsterdam Pharma Co N.V.

JWS

John W Smither

Chief Financial Officer

Solana Beach, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ARQT shares.

Notify only if

Value

Insider Trading

Get notified when an Arcutis Biotherapeutics, Inc. insider buys or sells ARQT shares.

Notify only if

Operation

Value

Type

News

Receive news related to Arcutis Biotherapeutics, Inc.

Track Activities on ARQT

Account